Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 2.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,388 shares of the medical equipment provider’s stock after selling 1,175 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Hologic were worth $3,560,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. First Horizon Advisors Inc. increased its holdings in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. Brooklyn Investment Group increased its holdings in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after acquiring an additional 145 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 159 shares during the period. Trivant Custom Portfolio Group LLC increased its holdings in shares of Hologic by 2.1% in the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after acquiring an additional 169 shares during the period. Finally, Loomis Sayles & Co. L P increased its holdings in shares of Hologic by 29.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock valued at $66,000 after acquiring an additional 183 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $61.47 on Monday. The firm has a market capitalization of $13.79 billion, a P/E ratio of 19.39, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a one year low of $60.34 and a one year high of $84.67. The company’s fifty day moving average is $66.06 and its two-hundred day moving average is $73.94. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on HOLX shares. Jefferies Financial Group started coverage on shares of Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective on the stock. Stephens reiterated an “overweight” rating and issued a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Morgan Stanley lowered their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Finally, Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Hologic has a consensus rating of “Hold” and a consensus price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.